PL3649151T3 - Białka rusztowania - Google Patents

Białka rusztowania

Info

Publication number
PL3649151T3
PL3649151T3 PL18740273.0T PL18740273T PL3649151T3 PL 3649151 T3 PL3649151 T3 PL 3649151T3 PL 18740273 T PL18740273 T PL 18740273T PL 3649151 T3 PL3649151 T3 PL 3649151T3
Authority
PL
Poland
Prior art keywords
scaffolding proteins
scaffolding
proteins
Prior art date
Application number
PL18740273.0T
Other languages
English (en)
Inventor
Geoff William PLATT
Graham Robert Pye-Smith SPENCE
Original Assignee
Avacta Life Sciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avacta Life Sciences Limited filed Critical Avacta Life Sciences Limited
Publication of PL3649151T3 publication Critical patent/PL3649151T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Optical Head (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
PL18740273.0T 2017-07-07 2018-07-02 Białka rusztowania PL3649151T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1710973.7A GB201710973D0 (en) 2017-07-07 2017-07-07 Scaffold proteins
PCT/GB2018/051855 WO2019008335A1 (en) 2017-07-07 2018-07-02 SCAFFOLD PROTEINS

Publications (1)

Publication Number Publication Date
PL3649151T3 true PL3649151T3 (pl) 2024-11-04

Family

ID=59676583

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18740273.0T PL3649151T3 (pl) 2017-07-07 2018-07-02 Białka rusztowania

Country Status (15)

Country Link
US (3) US11952415B2 (pl)
EP (2) EP3649151B1 (pl)
JP (1) JP7659292B2 (pl)
KR (1) KR102827597B1 (pl)
CN (1) CN111132999A (pl)
AU (3) AU2018295447B2 (pl)
CA (1) CA3067682A1 (pl)
ES (1) ES2990992T3 (pl)
GB (1) GB201710973D0 (pl)
IL (1) IL271340A (pl)
PL (1) PL3649151T3 (pl)
PT (1) PT3649151T (pl)
SG (1) SG11201912298QA (pl)
TW (1) TW201920256A (pl)
WO (1) WO2019008335A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス, インク.Flodesign Sonics, Inc. 音響トランスデューサドライバ及びコントローラ
CN108240696A (zh) * 2018-03-15 2018-07-03 重庆物奇科技有限公司 一种空调除霜除冰系统及方法
AU2020221274B2 (en) 2019-02-15 2024-02-08 Sigma-Aldrich Co. Llc. Crispr/Cas fusion proteins and systems
US20230002493A1 (en) * 2019-09-26 2023-01-05 Orionis Biosciences, Inc. Pd-l1 targeted chimeric proteins and uses thereof
EP4041295A4 (en) * 2019-10-09 2024-04-10 Edward Fritsch MULTI-DOMAIN PROTEIN VACCINE
EP4045536A4 (en) * 2019-10-16 2023-11-01 Lg Chem, Ltd. Neonatal fc receptor binding affimers
CN113045655A (zh) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
CN112851806B (zh) * 2021-01-15 2022-04-01 武汉大学 一种Homer的抗原肽及其抗体与应用
CN113801866B (zh) * 2021-09-02 2022-08-16 无锡佰翱得生物科学有限公司 一种高效表达具有高活性及稳定性的重组tev酶及其制备方法和应用
EP4413038A1 (en) * 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
CN115409174B (zh) * 2022-11-01 2023-03-31 之江实验室 一种基于dram存内计算的碱基序列过滤方法与装置
FR3147278A1 (fr) * 2023-03-31 2024-10-04 Avacta Life Sciences Limited Polypeptides de liaison au tnfr2 et procedes d'utilisation
FR3147292A1 (fr) * 2023-03-31 2024-10-04 Affyxell Therapeutics Co., Ltd. Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations
EP4688825A1 (en) * 2023-03-31 2026-02-11 AffyXell Therapeutics Co., Ltd. Tnfr2 binding polypeptides and methods of use
GB202403780D0 (en) 2024-03-15 2024-05-01 Avacta Life Sciences Ltd Polypeptides and methods for detecting and quantifying small molecules
WO2026002988A1 (en) * 2024-06-24 2026-01-02 Avacta Life Sciences Limited Fibroblast activation protein alpha binder proteins

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA94566A (en) 1905-07-17 1905-08-08 William H. Richmond Shipping crate
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE3851153T2 (de) 1987-12-11 1995-01-05 Hughes Howard Med Inst Genetische modifizierung von endothelialen zellen.
EP0456640A1 (en) 1988-12-13 1991-11-21 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Genetically engineered endothelial cells and use thereof
ES2084698T5 (es) 1989-05-04 2005-03-01 Southern Research Institute Procedimiento de encapsulacion.
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
CA2092195C (en) 1990-09-21 2000-04-18 Douglas J. Jolly Retroviral packaging cell line
ATE163046T1 (de) 1990-10-31 1998-02-15 Somatix Therapy Corp Genetische veränderung von endothelzellen
ATE188740T1 (de) 1991-02-19 2000-01-15 Univ California Viruspartikel mit veraendertem wirtspektrum
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
JPH08505625A (ja) 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性tリンパ球応答の誘導
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5767242A (en) 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE69704206T2 (de) 1996-08-16 2001-08-30 Medical Research Council, London Selbst-replizierende episomale expressionsvektoren, welche gewebespezifische expression vermitteln
US6413544B1 (en) 1996-08-19 2002-07-02 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
GB2330907A (en) 1997-10-28 1999-05-05 Applied Imaging Int Ltd A karyotyper and methods for producing karyotypes
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
NZ506245A (en) 1998-02-12 2003-08-29 Immune Complex Corp Strategically modified hepatitis b core proteins and their derivatives
WO2000002620A1 (en) 1998-07-13 2000-01-20 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2000067837A1 (en) 1999-05-10 2000-11-16 Gentronics, Inc. Method of electroporation-enhanced delivery of active agents
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20050250854A1 (en) 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
GB0108968D0 (en) 2001-04-10 2001-05-30 Imp College Innovations Ltd Methods
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
KR20060031610A (ko) 2003-05-30 2006-04-12 유니버시티 오브 사우스 플로리다 악성 종양 치료 방법
US7790446B2 (en) 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
US8101169B2 (en) 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
US7923251B2 (en) 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
WO2007053189A2 (en) 2005-06-01 2007-05-10 Northwestern University Compositions and methods for altering immune function
US8063019B2 (en) 2005-06-10 2011-11-22 Medical Research Council Scaffold polypeptides for heterologous peptide display
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP1995327A1 (en) 2007-05-21 2008-11-26 Humboldt Universität zu Berlin Probe for detecting a particular nucleic acid sequence
AU2008252853B2 (en) 2007-05-24 2011-12-01 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
DE102007052517A1 (de) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT-Verfahren mit zwei Filtersystemen
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
GB0807065D0 (en) 2008-04-18 2008-05-21 Univ Leeds Novel scaffolds
EP2346995B1 (en) 2008-09-26 2018-11-07 Tocagen Inc. Gene therapy vectors and cytosine deaminases
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
WO2010148203A2 (en) 2009-06-17 2010-12-23 Tocagen Inc. Producer cells for replication competent retroviral vectors
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP2632491A4 (en) 2010-10-31 2014-10-01 Tocagen Inc ENHANCED TREATMENT AND MONITORING OF CANCER USING RECOMBINANT VECTORS
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
JP6207509B2 (ja) 2011-08-30 2017-10-04 トラスティーズ オブ タフツ カレッジ 固形腫瘍を治療するためのfap活性化プロテアソーム阻害剤
HK1206612A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
EP2911736A4 (en) 2012-10-25 2016-06-15 Oncosec Medical Inc electroporation
JP6419706B2 (ja) 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター
GB201302597D0 (en) 2013-02-14 2013-04-03 Univ Leeds Novel Synthetic Proteins
CN105579581A (zh) 2013-08-05 2016-05-11 托卡根公司 具有优化的a凸出物的重组载体
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015105926A1 (en) 2014-01-08 2015-07-16 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
MX378753B (es) 2014-03-20 2025-03-10 Bristol Myers Squibb Co Dominios de fibronectina tipo iii que se unen a albúmina de suero.
JP6894236B2 (ja) 2014-03-26 2021-06-30 デノボ バイオファーマ エルエルシー 免疫刺激活性を有するレトロウイルスベクター
IL291922B1 (en) 2014-06-13 2026-01-01 Tufts College FAP-activated medical materials and related uses
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
US20170136132A1 (en) 2014-06-19 2017-05-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196130A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
MX383277B (es) 2015-01-09 2025-03-13 Oncosec Medical Inc Plasmido que codifica a un agonista coestimulador.
JP6313530B1 (ja) 2015-01-16 2018-04-18 アカデミア シニカAcademia Sinica 標的化成分及びエフェクター成分を有する分子構築物
US20180000953A1 (en) 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
US10426847B2 (en) 2015-03-26 2019-10-01 Oncosec Medical Incorporated Method for the treatment of malignancies
CN107872982B (zh) 2015-03-31 2022-10-28 昂科赛克医疗公司 用于改进的基于组织感测的电穿孔的系统和方法
WO2017036889A1 (en) 2015-08-28 2017-03-09 Biontech Rna Pharmaceuticals Gmbh Method for reducing immunogenicity of rna
MX2018002744A (es) 2015-09-04 2018-04-13 Tocagen Inc Vectores recombinantes que comprenden peptido 2a.
PL3350333T3 (pl) 2015-09-17 2022-03-07 Modernatx, Inc. Polinukleotydy zawierające region stabilizujący ogon
WO2017053617A1 (en) 2015-09-23 2017-03-30 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
EP3390643B8 (en) 2015-12-18 2023-08-02 OncoSec Medical Incorporated Plasmid constructs for heterologous protein expression and methods of use
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
JP2019517557A (ja) 2016-06-10 2019-06-24 アイオー セラピューティクス インコーポレイテッド 癌免疫療法のための受容体選択的レチノイドおよびレキシノイド化合物および免疫調節因子
WO2018056825A1 (en) 2016-09-23 2018-03-29 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Manipulation of immune activity by modulation of expression
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
GB201805963D0 (en) 2018-04-11 2018-05-23 Avacta Life Sciences Ltd PD-L1 Binding Affirmers and Uses Related Thereto
WO2019236567A2 (en) 2018-06-04 2019-12-12 Trustees Of Tufts College Tumor microenvironment-activated drug-binder conjugated, and uses related thereto
WO2021074683A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited Bispecific anti-pd-l1 and anti-fcrn polypeptides
EP4045536A4 (en) 2019-10-16 2023-11-01 Lg Chem, Ltd. Neonatal fc receptor binding affimers
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
TW202221031A (zh) 2020-07-30 2022-06-01 英商阿法克塔生命科學有限公司 血清半衰期延長之pd-l1抑制多肽
TW202221030A (zh) 2020-07-30 2022-06-01 英商阿法克塔生命科學有限公司 血清白蛋白結合多肽
KR20230141754A (ko) 2020-10-30 2023-10-10 아박타 라이프 사이언시스 리미티드 Fap-활성화 혈청 반감기 연장된 치료 접합체
KR20230141755A (ko) 2020-10-30 2023-10-10 아박타 라이프 사이언시스 리미티드 효소 활성화 혈청 반감기 연장된 치료 접합체

Also Published As

Publication number Publication date
EP3649151B1 (en) 2024-08-07
KR20200024869A (ko) 2020-03-09
IL271340A (en) 2020-01-30
AU2023208125B2 (en) 2025-04-03
EP4467650A2 (en) 2024-11-27
CA3067682A1 (en) 2019-01-10
JP7659292B2 (ja) 2025-04-09
AU2018295447A1 (en) 2020-01-16
US12286468B2 (en) 2025-04-29
US20250270293A1 (en) 2025-08-28
EP4467650A3 (en) 2025-04-02
TW201920256A (zh) 2019-06-01
US20240317839A1 (en) 2024-09-26
WO2019008335A1 (en) 2019-01-10
AU2018295447B2 (en) 2023-05-04
AU2023208125A1 (en) 2023-10-12
EP3649151A1 (en) 2020-05-13
PT3649151T (pt) 2024-09-05
JP2020532949A (ja) 2020-11-19
CN111132999A (zh) 2020-05-08
US11952415B2 (en) 2024-04-09
GB201710973D0 (en) 2017-08-23
US20200181239A1 (en) 2020-06-11
ES2990992T3 (es) 2024-12-02
KR102827597B1 (ko) 2025-07-02
AU2025202133A1 (en) 2025-04-10
SG11201912298QA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
PL3649151T3 (pl) Białka rusztowania
DK3731771T3 (da) V462033dk00
IL254516B (en) Proteins specific for cd137
EP3549340A4 (en) MULTI-HYPOTHESIS FUSION MODE
CL2018000524S1 (es) Golilla
DK3723783T3 (da) Mitokondrie-målrettede peptider
DK4089113T3 (da) Polypeptider
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3634404C0 (en) PYRAZOLE-BASED MAGL INHIBITORS
EP3588580A4 (en) SCHOTTKY MOS TRENCH DIODE
DK3351526T3 (da) Diisopentylterephthalat
IL254591A0 (en) Polypeptides
DK3568655T3 (da) Rekuperator
DK3571580T5 (da) Load-logical-and-shift-guarded-instruktion
HUE056166T2 (hu) Új rovargátló fehérjék
DK3612237T3 (da) Genterapi
EP3611402A4 (en) SERVO CYLINDER
IT201700036862A1 (it) Hangar migliorato
FI20155191L (fi) Nivel
DK3448879T3 (da) Claudin-6 peptider
DK3576686T3 (da) Brokbind
DK3568506T3 (da) Offeranode
EP3698005A4 (en) POST CLEARERS
EP3607993A4 (en) INTERCONNECTS
EP3424943A4 (en) PEPTIDE